SCYX:NSD-SCYNEXIS Inc.

EQUITY | Drug Manufacturers | NASDAQ Global Market

Last Closing Price

USD 1.84

Change

-0.02 (-1.08)%

Market Cap

USD 0.09B

Volume

0.29M

Yahoo Analyst Target

USD 5.56 (202.17%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-07-20 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
MYL Mylan N.V.

-0.11 (-0.31%)

USD 18.31B
HCM Hutchison China MediTech Limit..

+0.97 (+2.95%)

USD 4.50B
GWPH GW Pharmaceuticals Plc

-2.39 (-1.61%)

USD 4.12B
OPK Opko Health Inc.

-0.07 (-1.17%)

USD 3.30B
IRWD Ironwood Pharmaceuticals Inc.

-0.04 (-0.20%)

USD 3.04B
HRTX Heron Therapeutics Inc.

N/A

USD 3.03B
MDCO The Medicines Company

-0.28 (-0.70%)

USD 2.93B
AERI Aerie Pharmaceuticals Inc.

-0.50 (-0.68%)

USD 2.90B
HZNP Horizon Pharma plc

+0.10 (+0.58%)

USD 2.88B
SUPN Supernus Pharmaceuticals Inc.

+0.63 (+1.15%)

USD 2.84B

ETFs Containing SCYX

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -20.69% 24% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.69% 24% F 15% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -27.96% 8% F 5% F
Dividend Return -27.96% 8% F 5% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.30% 94% A 53% F
Risk Adjusted Return -110.49% 6% F 3% F
Market Capitalization 0.09B 34% F 26% F

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -2.14 39% F 65% D
Price/Book Ratio 4.00 43% F 31% F
Price / Cash Flow Ratio -0.47 39% F 71% C-
Price/Free Cash Flow Ratio -2.22 38% F 63% D
Management Effectiveness  
Return on Equity -82.58% 36% F 13% F
Return on Invested Capital -67.39% 38% F 14% F
Return on Assets -45.48% 44% F 15% F
Debt to Equity Ratio 51.75% 34% F 45% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

SCYX:NSD-SCYNEXIS Inc.

EQUITY | Drug Manufacturers | NASDAQ Global Market

Last Closing Price

USD 1.84

Change

-0.02 (-1.08)%

Market Cap

USD 0.09B

Volume

0.29M

Yahoo Analyst Target

USD 5.56 (202.17%)

STA Analyst Target

N/A
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-07-20